On a DART-filed basis, revenue fell from KRW 11 billion in 2022 to KRW 4.35 billion in 2023, a 60.5% decline, then rose to KRW 5.69 billion in 2024 and KRW 21.2 billion in 2025, marking two consecutive years of growth from 2024 through 2025. 2025 was the largest revenue year of the 2022 to 2025 period.
According to the company, the increase reflected strong domestic and overseas sales of its NGS panels and analysis software, plus the consolidation of the pharmaceutical wholesaler acquired in November 2025, and distribution revenue in 2025 was KRW 14.1 billion, or 66.6% of annual revenue.
The operating loss widened from KRW 8.6 billion in 2022 to KRW 13.4 billion in 2023 and KRW 16.1 billion in 2024, then narrowed to KRW 8.28 billion in 2025, extending a loss streak that runs four consecutive years from 2022 through 2025.
The operating margin moved from -78.1% in 2022 to -308.6% in 2023 and -282.5% in 2024, then improved to -39.0% in 2025, an improvement that appears driven largely by the larger revenue base.
Net loss attributable to controlling shareholders was KRW 9.79 billion in 2022, KRW 12.8 billion in 2023, KRW 12.6 billion in 2024 and KRW 5.54 billion in 2025. The net loss including non-controlling interests was KRW 6.76 billion in 2025, larger than the loss attributable to controlling shareholders.
Operating cash flow was negative in all four years, at -KRW 7.82 billion in 2022, -KRW 9.17 billion in 2023, -KRW 12.4 billion in 2024 and -KRW 8.48 billion in 2025.
On a quarterly basis, revenue in the fourth quarter of 2025 rose 120.5% from the prior quarter to KRW 12 billion, and third-quarter 2026 revenue of KRW 13.4 billion was up 147.5% year on year.
In the fourth quarter of 2025, the company swung to a profit attributable to controlling shareholders of KRW 4.48 billion despite an operating loss of KRW 1.9 billion, suggesting non-operating items were large, and whether that gain was one-off is the next point to check.
Attributable net losses continued in each quarter from the first quarter through the third quarter of 2026, and the four-quarter total from the fourth quarter of 2025 through the third quarter of 2026 was KRW 6.62 billion.